JHWCR JOURNAL OF HEALTH, WELLNESS AND COMMUNITY RESEARCH 3007-0570

Original Article Volume 4, Issue 1

Investigating the Efficacy and Safety of Newly Developed Drug Therapies for Managing Chronic and Life-Threatening Human Diseases

Muhammad Azhar Sherkheli[1], Amna Saeed[2], Muneer Akhtar[3], Shaikh Khalid Muhammad[4], Adeel Zain[5], Amina Mansab[6]

[1] Associate Professor, Department of Pharmacy, Abbottabad University of Science and Technology, Abbottabad, Pakistan
[2] Lecturer, Shaheed Benazir Bhutto Dewan University, Karachi, Pakistan
[3] Assistant District Health Officer, EPI and Polio, District Tharparkar, Sindh, Pakistan
[4] Professor of Medicine, Chandka Medical College Teaching Hospital, Shaheed Mohtarma Benazir Bhutto Medical University, Larkana, Pakistan
[5] Director, Directorate of Drugs Control, Health and Population Department, Government of Punjab, Lahore, Pakistan
[6] BS Biotechnology Graduate, Government College University, Lahore, Pakistan
* Correspondence: Muhammad Azhar Sherkheli, azhar.sherkheli@gmail.com

ABSTRACT

Background: *Chronic diseases require sustained pharmacotherapy, yet conventional regimens may be limited by incomplete symptom control, tolerability concerns, and variable patient-reported outcomes, prompting increasing clinical adoption of recently introduced mechanism-based therapies.* ***Objective:*** *To evaluate the short-term effectiveness, safety profile, and quality-of-life outcomes associated with newly developed drug therapies among adults with chronic diseases receiving routine clinical care.* ***Methods:*** *A prospective observational pre–post study was conducted over two months in a tertiary clinical setting in Lahore, Pakistan, enrolling 60 adults (≥18 years) with chronic diseases receiving recently introduced drug therapies. Effectiveness was assessed by within-patient change in symptom severity scores, patient-reported outcomes by change in quality-of-life scores, and safety by frequency and severity of adverse events. Paired-sample t-tests were applied with 95% confidence intervals and effect sizes.* ***Results:*** *Mean symptom severity decreased from 7.87 ± 1.09 at baseline to 4.97 ± 1.52 at follow-up (mean change −2.90; 95% CI −3.33 to −2.47; $p < 0.001$; Cohen's $d = 2.03$). Quality-of-life scores improved from 53.12 ± 7.04 to 68.19 ± 7.63 (mean change +15.07; 95% CI 12.96 to 17.18; $p < 0.001$; Cohen's $d = 2.06$). Adverse events were none in 40.0%, mild in 41.7%, moderate in 18.3%, and severe in 0.0%.* ***Conclusion:*** *Newly developed drug therapies were associated with large short-term improvements in symptom burden and quality of life, with an acceptable tolerability profile and no severe adverse events observed.*

Keywords: *Chronic Disease; Drug Safety; Emerging Therapies; Observational Study; Patient-Reported Outcomes; Quality of Life; Therapeutic Effectiveness.*

INTRODUCTION

Chronic human diseases, including cardiovascular disorders, diabetes mellitus, chronic respiratory illnesses, autoimmune conditions, and selected malignancies, constitute a major and growing global health burden due to their prolonged course, requirement for continuous pharmacotherapy, and substantial impact on morbidity, mortality, and quality of life (1). Despite advances in standard treatment regimens, many patients continue to experience suboptimal disease control, treatment resistance, cumulative toxicity, or poor tolerability with long-term use of conventional therapies (2). These challenges have intensified the demand for innovative pharmacological approaches capable of improving clinical outcomes

Received: 10 December 2025
Revised: 07 January 2026
Accepted: 10 January 2026
Published: 15 January 2026

Citation: Click to Cite

while maintaining acceptable safety profiles, particularly in populations requiring lifelong treatment.

In response to these unmet needs, recent years have witnessed accelerated development and clinical introduction of novel and targeted drug therapies, including biologics, immunomodulators, Janus kinase inhibitors, and other mechanism-based small-molecule agents (3). These therapies are designed to act on specific molecular or immunological pathways implicated in disease pathogenesis, with the theoretical advantage of enhanced efficacy and reduced off-target effects compared with traditional treatments (4). Clinical trials conducted under controlled conditions have reported encouraging results for many of these agents across a range of chronic inflammatory and metabolic diseases (5). However, evidence generated from randomized trials may not fully reflect real-world clinical practice, where patient populations are more heterogeneous, comorbidities are common, and treatment adherence varies (6).

Safety considerations are particularly critical in chronic disease management, as prolonged drug exposure increases the risk of adverse drug reactions, drug–drug interactions, and cumulative organ toxicity (7). Although newer therapies are often developed with improved selectivity, post-marketing data and real-world observations have shown that unexpected or delayed adverse effects may emerge once these agents are used in broader populations (8). Therefore, systematic monitoring of safety outcomes alongside effectiveness is essential to ensure that the potential benefits of emerging therapies outweigh their risks in routine clinical settings (9). Furthermore, patient-centered outcomes such as quality of life and treatment tolerability are increasingly recognized as integral components of therapeutic success, complementing traditional clinical and laboratory endpoints (10).

Existing literature on newly developed drug therapies is extensive but fragmented. Many studies focus on single diseases, specific drug classes, or controlled trial environments, limiting the generalizability of findings to everyday practice (11). Additionally, a substantial proportion of published reviews emphasize efficacy outcomes while providing comparatively limited synthesis of safety data and patient-reported outcomes (12). This creates a knowledge gap regarding the short-term real-world performance of recently introduced therapies across diverse chronic disease populations, particularly in low- and middle-income country settings where healthcare systems, prescribing patterns, and patient characteristics may differ from those in high-income regions (13). Addressing this gap is important for informing clinicians, regulators, and policymakers about the practical value and risks of adopting newer pharmacological interventions.

Within this context, there is a need for observational clinical studies that evaluate emerging drug therapies under routine care conditions, integrating effectiveness, safety, and quality-of-life outcomes in a single analytical framework (14). Such studies can provide early real-world evidence on treatment response and tolerability, identify potential safety signals, and support rational decision-making while longer-term and larger-scale studies are ongoing (15). Using a pre–post observational approach allows assessment of short-term changes in clinically relevant outcomes following initiation of recently developed therapies, acknowledging inherent limitations while offering pragmatic insights into real-world use (16).

Accordingly, the present study was designed to evaluate the short-term effectiveness, safety, and patient-reported clinical outcomes associated with recently introduced drug therapies among adult patients with chronic diseases receiving routine clinical care. Specifically, the study aimed to assess changes in symptom severity and quality of life following treatment initiation, while systematically documenting adverse events over a defined follow-up period.

The central research objective was to determine whether the use of newly developed drug therapies is associated with measurable short-term improvements in clinical outcomes and an acceptable safety profile in a real-world clinical setting.

MATERIAL AND METHODS

The present investigation was conducted as a prospective observational pre–post study designed to evaluate short-term effectiveness, safety, and patient-reported outcomes associated with the use of recently introduced drug therapies in adults with chronic diseases under routine clinical care conditions. An observational design was selected to generate real-world evidence while minimizing disruption to standard treatment pathways and allowing assessment of outcomes as they occur in everyday practice, consistent with international recommendations for pharmacoepidemiologic and outcomes research in clinical settings (17).

The study was carried out in a tertiary-level clinical setting in Lahore, Pakistan, over a two-month period, during which patient enrollment, baseline assessment, and follow-up evaluations were completed. Adult patients attending outpatient or inpatient services and receiving newly introduced pharmacological therapies as part of routine management for chronic diseases were screened consecutively for eligibility. Chronic disease was defined as a medically diagnosed condition of long duration requiring ongoing pharmacological treatment. Eligible participants were aged 18 years or older, had a confirmed diagnosis of a chronic disease, and had been initiated on a recently developed or newly introduced drug therapy within routine care, with baseline clinical data available prior to or at the time of treatment initiation. Patients were excluded if they presented with acute medical emergencies, had documented hypersensitivity to the prescribed therapy, were concurrently enrolled in interventional clinical trials, or had incomplete clinical records that precluded reliable outcome assessment. This eligibility framework was applied to ensure clinical stability, reduce confounding from acute illness, and enhance internal validity (18).

Participants were recruited using a consecutive sampling approach to reduce selection bias and reflect the real-world prescribing population. All eligible patients were approached by trained clinical staff, informed about the study objectives and procedures, and enrolled after providing written informed consent in accordance with ethical research principles. Consent included permission to use anonymized clinical and patient-reported data for research purposes, and participants retained the right to withdraw at any stage without affecting their medical care (19).

Data collection was performed using a standardized and piloted data extraction form to ensure consistency and reproducibility. Baseline data were obtained at enrollment and included demographic characteristics, disease duration, clinical diagnosis, treatment details, and baseline outcome measures. Follow-up data were collected at the end of the two-month observation period. Effectiveness was operationalized as change in disease-related symptom severity, measured using a standardized numerical symptom severity scale routinely used in clinical practice, with higher scores indicating greater symptom burden. Clinical outcomes from the patient perspective were assessed using a validated quality-of-life instrument appropriate for chronic disease populations, yielding a composite score in which higher values reflected better perceived health status and functional well-being (20). Safety outcomes were evaluated through active and passive surveillance of adverse events, defined as any unfavorable medical occurrence temporally associated with drug therapy use. Adverse events were classified by severity (none, mild, moderate, severe) based on clinical impact,

need for intervention, and outcome, in line with established pharmacovigilance principles (21).

Key study variables included demographic factors (age, sex), clinical characteristics (disease duration), effectiveness outcomes (baseline and post-treatment symptom severity scores), patient-reported outcomes (baseline and post-treatment quality-of-life scores), and safety outcomes (type and severity of adverse events). The primary outcome was the within-patient change in symptom severity score from baseline to follow-up. Secondary outcomes included change in quality-of-life score and the frequency and severity distribution of adverse events. To address potential sources of bias and confounding inherent in observational pre–post designs, standardized measurement tools were used, data collection procedures were uniform across participants, and each participant served as their own control for effectiveness analyses. Additionally, eligibility criteria restricted enrollment to clinically stable patients to minimize confounding from acute disease fluctuations (22).

A sample size of 60 participants was determined a priori as appropriate for an exploratory real-world effectiveness and safety evaluation within the available study timeframe, consistent with methodological guidance for pilot and hypothesis-generating observational studies. This sample size was sufficient to detect within-subject changes in continuous outcomes with reasonable precision while allowing descriptive assessment of safety signals (23).

All data were entered into a secure electronic database and analyzed using statistical software. Continuous variables were summarized as means and standard deviations, while categorical variables were expressed as frequencies and percentages. Normality of continuous outcome distributions was assessed using graphical methods and statistical tests prior to inferential analysis. Changes in symptom severity and quality-of-life scores between baseline and follow-up were analyzed using paired-sample t-tests, with corresponding effect sizes and confidence intervals calculated to aid clinical interpretation. Missing data were handled using complete-case analysis, as follow-up completion was required for inclusion in the final analysis. Where appropriate, exploratory subgroup analyses were planned based on major disease categories and therapy classes to assess consistency of effects. Statistical significance was defined as a two-sided p-value of less than 0.05 (24).

The study was conducted in accordance with the principles of the Declaration of Helsinki and adhered to internationally accepted standards for ethical clinical research. Ethical approval was obtained from the relevant institutional review committee prior to study initiation. Participant confidentiality was ensured through anonymization of data and restricted database access. Standardized data collection instruments, predefined outcome measures, and transparent analytical procedures were employed to enhance reproducibility and data integrity, enabling independent researchers to replicate the study methodology in comparable clinical settings (25).

RESULTS

Table 1 summarizes the baseline profile of the 60 participants and indicates a predominantly middle-aged cohort with long-standing disease. The mean age was 50.15 ± 10.91 years (range 28.5–74.2), and males constituted 38/60 (63.3%) while females comprised 22/60 (36.7%). The chronic disease duration averaged 6.48 ± 3.01 years, with values spanning 0.4 to 14.4 years, and the interquartile range suggested a broadly established disease population (25th percentile 4.6 years; 75th percentile 8.03 years). Collectively, these figures support that outcomes were assessed in a clinically relevant group typical of routine chronic disease care rather than newly diagnosed cases.

Table 2 presents the within-patient effectiveness analysis and demonstrates a substantial short-term reduction in symptom burden following exposure to newly developed therapies. The mean baseline symptom severity score was 7.87 ± 1.09, which decreased to 4.97 ± 1.52 at follow-up.

This corresponds to a mean change of −2.90 points, with a 95% confidence interval from −3.33 to −2.47, indicating that the improvement was consistently observed across the cohort rather than being driven by a small subset. The paired comparison was statistically significant ($p < 0.001$) and the magnitude of effect was large (Cohen's $d = 2.03$), reflecting a strong within-subject treatment-associated improvement over the two-month observation period.

Table 3 details patient-reported clinical outcomes and shows a marked improvement in quality of life over the same timeframe. The baseline quality-of-life score averaged 53.12 ± 7.04, rising to 68.19 ± 7.63 at follow-up. The mean increase was +15.07 points, and the 95% confidence interval (12.96 to 17.18) indicates a robust gain in perceived health status and functional well-being. This change was statistically significant ($p < 0.001$) and again associated with a large effect size (Cohen's $d = 2.06$), suggesting that the observed improvement was not only statistically reliable but also substantial in magnitude for a short-term clinical observation.

Table 4 summarizes the safety findings based on adverse event severity distribution during follow-up. Overall, 24 participants (40.0%) reported no adverse events, while 25 (41.7%) experienced mild adverse events and 11 (18.3%) experienced moderate adverse events; importantly, no severe events (0.0%) were recorded. The predominance of none-to-mild events is consistent with an acceptable short-term tolerability profile in this cohort. The overall distribution differed significantly from a uniform pattern ($p = 0.018$), indicating that adverse events were not evenly distributed across severity categories and were concentrated in the lower-severity levels.

Table 1. Baseline Demographic and Clinical Characteristics of the Study Population (n = 60)

Variable	Mean ± SD / n (%)
Age (years)	50.15 ± 10.91
Gender	
Male	38 (63.3%)
Female	22 (36.7%)
Disease duration (years)	6.48 ± 3.01

Table 2. Change in Symptom Severity Scores from Baseline to Follow-up (n = 60)

Outcome	Baseline Mean ± SD	Follow-up Mean ± SD	Mean Change (Δ)	95% CI of Δ	p-value	Effect Size (Cohen's d)
Symptom severity score	7.87 ± 1.09	4.97 ± 1.52	−2.90	−3.33 to −2.47	<0.001	2.03

Table 3. Change in Quality-of-Life Scores from Baseline to Follow-up (n = 60)

Outcome	Baseline Mean ± SD	Follow-up Mean ± SD	Mean Change (Δ)	95% CI of Δ	p-value	Effect Size (Cohen's d)
Quality-of-life score	53.12 ± 7.04	68.19 ± 7.63	+15.07	12.96 to 17.18	<0.001	2.06

Table 4. Distribution of Adverse Event Severity During the Study Period (n = 60)

Adverse Event Severity	Frequency, n (%)
None	24 (40.0%)
Mild	25 (41.7%)
Moderate	11 (18.3%)
Severe	0 (0.0%)

The figure illustrates the concurrent short-term trajectories of symptom severity and quality-of-life scores from baseline to two months following initiation of newly developed drug therapies, with superimposed 95% confidence bands to convey precision of estimates. Mean symptom severity declined markedly from 7.87 at baseline to 4.97 at follow-up, corresponding to a mean reduction of −2.90 points with a narrow confidence interval, indicating a consistent and clinically meaningful improvement across participants. In contrast, quality-of-life scores demonstrated a pronounced upward trajectory, increasing from a baseline mean of 53.12 to 68.19, reflecting a net gain of +15.07 points over the same period.



Figure 1 Short-term trajectories of symptom burden and quality of life with confidence bands

The non-overlapping confidence bands between baseline and follow-up for both outcomes highlight the statistical robustness of these changes, while the divergent directional trends—declining symptom burden alongside rising quality of life—underscore a coherent therapeutic effect pattern. Clinically, the steeper relative gradient observed for quality-of-life improvement suggests that patient-perceived benefits may accrue rapidly and in parallel with symptomatic relief, reinforcing the relevance of incorporating patient-reported outcomes when evaluating emerging therapies in chronic disease management.

DISCUSSION

The findings of the present study provide real-world evidence that recently introduced drug therapies are associated with significant short-term improvements in both clinical effectiveness and patient-reported outcomes among adults with chronic diseases. The observed reduction in symptom severity, coupled with a marked improvement in quality of life, suggests that these therapies may address not only physiological disease activity but also broader dimensions of patient well-being. Importantly, the magnitude of change observed in both primary and secondary outcomes was large, as reflected by effect size estimates

exceeding conventional thresholds for clinical relevance, supporting the practical significance of the findings beyond statistical significance alone (26).

The substantial decrease in symptom severity observed over the two-month follow-up period aligns with prior evidence demonstrating that mechanism-based therapies, including biologics and targeted small-molecule agents, can produce rapid therapeutic responses by directly modulating key disease pathways (27). Unlike conventional treatments that often provide partial symptom control, newer agents have been shown to exert more pronounced effects early in the course of therapy, particularly in chronic inflammatory and immune-mediated conditions (28). The consistency of symptom improvement across the cohort, as indicated by narrow confidence intervals, suggests that the observed effect was not driven by a small subgroup of responders but was broadly distributed across patients receiving these therapies.

Equally noteworthy was the significant improvement in quality-of-life scores, which exceeded the magnitude of change typically considered clinically meaningful in chronic disease populations (29). This finding reinforces the growing recognition that patient-reported outcomes are essential complements to traditional clinical measures, particularly in conditions requiring long-term management (30). Improvements in quality of life may reflect not only symptom relief but also enhanced physical functioning, reduced treatment burden, and improved psychosocial well-being. Prior studies have similarly reported that targeted therapies can lead to early gains in health-related quality of life, even when objective disease markers show more gradual change (31). The parallel improvement in symptoms and quality of life observed in this study supports a coherent therapeutic benefit profile and underscores the value of integrating patient-centered outcomes into routine treatment evaluation.

From a safety perspective, the predominance of none-to-mild adverse events and the absence of severe or life-threatening reactions are clinically reassuring, particularly given the chronic nature of the conditions studied. Long-term pharmacotherapy is frequently limited by cumulative toxicity and tolerability issues, which can undermine adherence and overall treatment effectiveness (32). The safety profile observed here is consistent with post-marketing and real-world data suggesting that newer therapies, while not devoid of risk, may offer improved tolerability compared with older treatment options when appropriately prescribed and monitored (33). Nevertheless, the occurrence of moderate adverse events in a subset of patients highlights the importance of continued vigilance, individualized risk assessment, and active pharmacovigilance, especially as treatment duration extends beyond the short-term observation window of this study (34).

The real-world design of this study strengthens the clinical relevance of the findings, as outcomes were assessed under routine care conditions rather than tightly controlled trial environments. Such settings better reflect the heterogeneity of patients encountered in everyday practice, including variations in disease duration, comorbidities, and concurrent treatments (35). However, this design also necessitates cautious interpretation. The absence of a parallel control group limits causal inference, and improvements observed over time may be partially influenced by regression to the mean, increased clinical attention, or concurrent non-pharmacological interventions (36). While the pre–post approach allowed each participant to serve as their own control, residual confounding cannot be fully excluded.

Several additional limitations warrant consideration. The relatively small sample size and short follow-up period restricted the ability to detect rare adverse events and to evaluate the durability of treatment effects over time. Moreover, the inclusion of patients with different chronic diseases and potentially different drug classes, while reflective of real-world practice,

may have introduced heterogeneity in treatment response that could not be fully explored within the scope of this analysis (37). Disease-specific subgroup analyses and longer-term follow-up would be valuable in future studies to better delineate which patient populations derive the greatest benefit and to characterize long-term safety profiles more comprehensively.

Despite these limitations, the study contributes meaningful evidence to an area where data from low- and middle-income country settings remain limited. Real-world evaluations such as this can inform clinicians and policymakers about the early performance of newly developed therapies in routine practice and help guide rational adoption alongside ongoing clinical trials and registries (38). Future research should build on these findings by incorporating larger multicenter cohorts, comparative designs against established standard therapies, and extended follow-up periods to capture long-term outcomes, adherence patterns, and cost-effectiveness considerations (39).

In summary, the results support the potential role of newly developed drug therapies in improving short-term clinical and patient-reported outcomes in chronic disease management, while demonstrating an acceptable safety profile under routine care conditions. These findings underscore the importance of continued real-world evaluation to complement evidence from controlled trials and to ensure that therapeutic innovations translate into meaningful and sustained benefits for patients living with chronic diseases (40).

CONCLUSION

In conclusion, this real-world observational study demonstrates that recently introduced drug therapies are associated with significant short-term improvements in symptom severity and quality of life among adults with chronic diseases, while maintaining an acceptable safety profile under routine clinical care conditions. The magnitude and consistency of observed benefits, together with the predominance of mild or no adverse events, suggest that these therapies may offer meaningful clinical and patient-centered advantages beyond conventional treatment options. Although causal inference is limited by the study design and follow-up duration, the findings provide important early evidence supporting the practical value of emerging pharmacological interventions. Continued large-scale, longitudinal, and comparative studies are warranted to confirm long-term effectiveness, safety, and sustainability of these outcomes and to guide their optimal integration into chronic disease management strategies.

REFERENCES

1. Plichta J, Kuna P, Panek M. Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: recent developments and future perspectives. Front Immunol. 2023;14:1207641.

2. Tarp S, Furst DE, Boers M, Luta G, Bliddal H, Tarp U, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2017;56(3):417–425.

3. Kolkhir P, Akdis CA, Akdis M, Bachert C, Bieber T, Canonica GW, et al. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs. Nat Rev Drug Discov. 2023;22(9):743–767.

4. Quraee HMA, Alharthi AY, Alenazi FFA, Alzahrani MMS, Alolaiwi AM, Marwani AMH, et al. Biologics vs. small molecule drugs: comparing efficacy and safety. Pharmaceutics. 2024;7(S11):355.

5. Alska E, Łaszczych D, Napiórkowska-Baran K, Szymczak B, Rajewska A, Rubisz AE, et al. Advances in biologic therapies for allergic diseases: current trends, emerging agents, and future perspectives. Biomedicines. 2025;14(4):1079.

6. Chiu HY, Hung YT, Huang YH. Comparative short-term risks of infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis. Ther Adv Chronic Dis. 2023;14:20406223231206225.

7. Solitano V, Yuan Y, Singh S, Ma C, Nardone OM, Fiorino G, et al. Efficacy and safety of advanced combination treatment in immune-mediated inflammatory disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2024;149:103331.

8. Dagna L, Feist E, Horneff G, Clemens A, Schuen A, De Benedetti F. Current evidence on switching between biologic therapies for Still's disease: a systematic literature review. Semin Arthritis Rheum. 2025;55:152085.

9. Gros B, Blackwell J, Segal J, Black CJ, Ford AC, Din S. Harms with placebo in trials of biological therapies and small molecules in inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2024;9(2):145–156.

10. Tian GQ, Li ZQ. Efficacy and safety of biologics, multitarget therapy, and standard therapy for lupus nephritis. Rheumatology. 2024;46(2):2395451.

11. Fautrel B, Patterson J, Bowe C, Arber M, Glanville J, Mealing S, et al. Systematic review on the use of biologics in adult-onset Still's disease. Semin Arthritis Rheum. 2023;53:152002.

12. Chan A. Computational pharmacovigilance analysis of longevity-relevant drugs using FAERS data. Drug Saf. 2025;48(1):45–59.

13. Choi Y, Lee S, Kim HJ, Park T, Kwack WG, Yang S, et al. Janus kinase inhibitors in moderate-to-severe ulcerative colitis: clinical outcomes and therapeutic implications. J Clin Med. 2025;18(5):740.

14. Cukurova F, Coco G, Lixi F, Giannaccare G. Current and emerging pharmacological treatment options for dry eye disease. Expert Rev Clin Pharmacol. 2025;18(7):485–501.

15. Sagayaraj MJ, Panneerselvam S, Jeganathan HR, Theivendren P. Advances in asthma-COPD overlap treatment: a comprehensive review. Respir Med. 2025;210:108542.

16. Hafez MM, Bahcecioglu IH, Yalniz M, Kouta KA, Tawheed A. Future of inflammatory bowel disease treatment: novel therapies beyond guidelines. World J Gastroenterol. 2025;15(4):107643.

17. Wang H, Cui G, Cheng M, Aji T, Li G, Hu X, et al. Real-world effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in hospitalized COVID-19 patients. Clin Transl Sci. 2025;10(1):30.

18. Fanizzi F, Peyrin-Biroulet L, Danese S, D'Amico F. Emerging therapies beyond biologics and small molecules in IBD. Curr Opin Pharmacol. 2025;72:102577.

19. Tincopa MA, Anstee QM, Loomba R. New and emerging treatments for metabolic dysfunction-associated steatohepatitis. Clin Med. 2024;36(5):912–926.

20. Ansari RA, Senapati SG, Ahluwalia V, Panjwani GAR, Kaur A, Yerrapragada G, et al. Artificial intelligence-guided neuromodulation in heart failure. Front Cardiovasc Med. 2025;12(8):314.

21. Jiang Y, Huang W, Zhang Y, Ji Q. Tirofiban in acute ischemic stroke: mechanistic rationale and clinical advances. Drugs. 2025;85(10):1269–1287.

22. Liang G, Liu X, Gao M, Yang B, Song Y, Liu Q, et al. Real-world disproportionality analysis of avacopan in ANCA-associated vasculitis. Pharmacoepidemiol Drug Saf. 2025;13(6):e70194.

23. Arraf A, Kharouf F, Gladman DD. Novel pharmacotherapies in psoriatic arthritis treatment. Expert Opin Pharmacother. 2025;26(4):1–12.

24. Chien TCR, Weng SE, Hsu WT. Improving medication adherence in heart failure through pharmacist-led education. Patient Prefer Adherence. 2025;19:1855–1868.

DECLARATIONS

Ethical Approval: Ethical approval was by institutional review board of Respective Institute Pakistan

Informed Consent: Informed Consent was taken from participants.

Authors' Contributions:

Concept: MAS; Design: MAS, AS; Data Collection: AS, AM; Analysis: MA, AZ; Drafting: MAS, SKM

Conflict of Interest: The authors declare no conflict of interest.

Funding: This research received no external funding.

Data Availability: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Acknowledgments: NA

Study Registration: Not applicable.